683 Capital Management’s Fennec Pharmaceuticals FENC Stock Holding History

683 Capital Management’s Portfolio FENC Stock Details FENC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-48,108	Closed	-$535K	–	152
2024 Q1	$535K	Sell	48,108 -91,892	-66%	-$923K	0.04%	96
2023 Q4	$1.57M	Sell	140,000 -160,000	-53%	-$1.33M	0.13%	85
2023 Q3	$2.25M	Hold	300,000	–	–	0.18%	83
2023 Q2	$2.65M	Hold	300,000	–	–	0.19%	89
2023 Q1	$2.5M	Hold	300,000	–	–	0.19%	112
2022 Q4	$2.88M	Sell	300,000 -84,824	-22%	-$751K	0.24%	90
2022 Q3	$3.12M	Sell	384,824 -40,514	-10%	-$278K	0.24%	84
2022 Q2	$2.37M	Sell	425,338 -58,980	-12%	-$342K	0.17%	104
2022 Q1	$2.71M	Sell	484,318 -224,982	-32%	-$1.13M	0.15%	105
2021 Q4	$3.12M	Sell	709,300 -400,700	-36%	-$2.98M	0.11%	107
2021 Q3	$10.5M	Hold	1,110,000	–	–	0.41%	56
2021 Q2	$8.09M	Hold	1,110,000	–	–	0.28%	72
2021 Q1	$6.89M	Hold	1,110,000	–	–	0.36%	60
2020 Q4	$8.27M	Hold	1,110,000	–	–	0.39%	54
2020 Q3	$6.73M	Hold	1,110,000	–	–	0.49%	46
2020 Q2	$9.27M	Buy	1,110,000 +160,000	+17%	+$1.19M	0.74%	31
2020 Q1	$5.64M	Hold	950,000	–	–	0.66%	37
2019 Q4	$6.17M	Sell	950,000 -21,351	-2%	-$115K	0.71%	35
2019 Q3	$4.67M	Hold	971,351	–	–	0.52%	48
2019 Q2	$3.88M	Hold	971,351	–	–	0.35%	59
2019 Q1	$4.71M	Hold	971,351	–	–	0.43%	52
2018 Q4	$6.2M	Hold	971,351	–	–	0.38%	51
2018 Q3	$7.96M	Buy	971,351 +104,166	+12%	+$966K	0.52%	44
2018 Q2	$9.05M	Hold	867,185	–	–	0.61%	36
2018 Q1	$10.5M	Hold	867,185	–	–	0.93%	32
2017 Q4	$8.69M	Buy	867,185 +58,820	+7%	+$587K	0.73%	42
2017 Q3	$8.87M	Buy	+808,365	New	+$9.39M	0.93%	38

Other funds holding FENC

SCA

Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return

SGL

Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return

DCM

DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return

SCM

Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HFA

Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

683 Capital Management's FENC Position: Q2 2024 in Review

683 Capital Management sold out of Fennec Pharmaceuticals (FENC) in Q2 2024, closing a stake of 48,108 shares — an estimated $535K sold.

683 Capital Management first reported a position in FENC in Q3 2017 and held it in 27 quarters. The position peaked at $10.5M in Q1 2018. 64 funds tracked by Wall St. Rank hold FENC as of Q2 2024.

683 Capital Management reported no remaining Fennec Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
683 Capital Management sold 48,108 Fennec Pharmaceuticals shares in Q2 2024, an estimated $535K.
683 Capital Management first reported a position in Fennec Pharmaceuticals in Q3 2017 and held it in 27 quarters.
683 Capital Management's Fennec Pharmaceuticals position peaked at $10.5M in Q1 2018.
64 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2024.

Based on 683 Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.